Atripla and Etoposide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Atripla (efavirenz; emtricitabine; tenofovir disoproxil fumarate) and Etoposide (etoposide). Common drug interactions include gastroenteritis among females and renal failure among males.

The phase IV clinical study analyzes what interactions people have when they take Atripla and Etoposide. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Atripla?

Atripla has active ingredients of efavirenz; emtricitabine; tenofovir disoproxil fumarate. It is often used in hiv infection. eHealthMe is studying from 36,036 Atripla users. Check the latest studies of Atripla.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

On Jul, 23, 2026

14 people who take Atripla and Etoposide together, and have interactions are studied.

Atripla and Etoposide drug interactions.

What are the common drug interactions of Atripla and Etoposide, by gender? *:

female:

Gastroenteritis (inflammation of stomach and intestine)
Renal failure (kidney dysfunction)
Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream)
Anaemia (lack of blood)
Burning sensation
Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
Diarrhoea
Febrile neutropenia (fever with reduced white blood cells)
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)

male:

Renal failure (kidney dysfunction)
Bacterial sepsis
Drug ineffective
Herpes zoster
Malaise (a feeling of general discomfort or uneasiness)
Neoplasm progression (growth of tumour)
Neuropathy peripheral (surface nerve damage)
Thrombocytopenia (decrease of platelets in blood)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)
White blood cell count decreased

What are the common drug interactions of Atripla and Etoposide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Burning sensation
Diabetic neuropathy (neuropathic disorders that are associated with diabetes mellitus)
Diarrhoea
Hypokalaemia (low potassium)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Malaise (a feeling of general discomfort or uneasiness)
Malaria (a parasitic disease due to mosquito bite)
Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
Muscular weakness (muscle weakness)
Neoplasm malignant (cancer tumour)

40-49:

Drug ineffective
Febrile neutropenia (fever with reduced white blood cells)
Herpes zoster
Neuropathy peripheral (surface nerve damage)
Thrombocytopenia (decrease of platelets in blood)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Kaposi's Sarcoma Aids Related (a tumour caused by human herpes virus associated with aids): 4 people, 28.57%
Kaposi's Sarcoma (a tumour caused by human herpes virus): 3 people, 21.43%
Hodgkin's Lymphoma (cancer originating from white blood cells): 3 people, 21.43%
Transplant Failure (transplantation failed to meet outcome): 2 people, 14.29%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 7.14%
Plasmablastic Lymphoma (aggressive b-cell cancer occurring mainly in the jaws and oral cavity): 1 person, 7.14%
Pain: 1 person, 7.14%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 7.14%
Neuropathy Peripheral (surface nerve damage): 1 person, 7.14%
Burkitt's Lymphoma (cancer of the lymphatic system): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Atripla and Etoposide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously